Publication | Closed Access

Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period

Pain TherapyPain DisordersHealth SciencesCrossover TrialPain MedicineMedicineBreakthrough PainPharmacologyPhase IiiCancer PainPharmacotherapyPain ManagementOncologyRadiation OncologyCancer ResearchAnalgesicsPain Research